Bausch Health Companies Inc. (BHC) research
Bausch Health Companies Inc.- Sector
- Pharmaceuticals
- Last price
- $5.81
- As of
Bausch Health Companies Inc. (BHC): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-07-30.
As of . Source: SEC EDGAR filings for BHC. Method and limitations.
Share the BHC intelligence card
See BHC live in the terminal
Track BHC's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live BHC terminal, freeActive signals for BHC
- highCONSENSUS_BUY
3 tracked funds increased BHC this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased BHC this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +66% to BHC (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +151% to BHC (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 74% of BHC (2026Q2)
FREE, NO ACCOUNT
Every signal on BHC, as it fires
You are seeing 5 of 27 signals recorded on BHC since 2026-05-30.
The five above landed across 2 days. The other 22 were recorded on 3 other days. 18 of the 27 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in BHC (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 071734107 · 2026Q2 | $13.3M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 071734107 · 2026Q2 | $11M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 071734107 · 2026Q2 | $10.5M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 071734107 · 2026Q2 | $6.5M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 071734107 · 2026Q2 | $5.4M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 071734107 · 2026Q2 | $5.4M | 0.00% | , |
| Bridgewater Associates, LPCUSIP 071734107 · 2026Q2 | $4.3M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, BHC
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
BHC against its peers
BHC's operating margin of 17.7% ranks in the 78th percentile of 19 Pharmaceuticals sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | BHC | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 10.3B USD | 451M USD | 98 | 21 |
| Gross margin | n/a | 53.3% | n/a | 7 |
| Operating margin | 17.7% | 2.6% | 78 | 19 |
| Net margin | 1.5% | -2.6% | 60 | 20 |
| Return on equity | n/a | -14.3% | n/a | 22 |
| P / E | 13.8x | 15.3x | 35 | 9 |
Peers (25): TRVI, NUVB, OCUL, NKTR, SUPN, HRMY, GPCR, ANIP, XERS, OMER, INVA, PAHC, OGN, AMLX, TARS, ANRO, ALMS, AMPH, PCRX, ESPR, ACRS, LQDA, AMRX, COLL, AXSM. Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (BHC: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more BHC signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to BHCand get the insider, 13F, options, and confluence read in one view.